Supplemental Table 3A. Distribution of Charlson comorbidity score using encounters only from the 12 months prior to diagnosis compared to using encounters from 12 months prior to 6 months following diagnosis

	Comorbidity score based on including only encounters in the 12 months prior to diagnosis N= 1,560,936		Comorbidity score based on including 12 months prior and 6 months after diagnosis N= 2,583,704	
Charlson Comorbidity Score	N	%	N	%
0	894,481	57.30%	1,554,800	60.18%
1	352,214	22.56%	570,080	22.06%
2	150,253	9.63%	220,191	8.52%
3 or higher	163,988	10.51%	238,633	9.24%

Supplemental Table 3B. Prevalence of Charlson comorbidity index conditions identified by including encounters from different time windows

Comorbidity	Prevalence of conditions in cases with encounters 12 months prior to diagnosis only	Prevalence of conditions in cases with encounters 12 months prior to diagnosis to 6 months after diagnosis	Prevalence of conditions in extra cases added* by extending time window to 6 months after diagnosis
Acute myocardial infarction	1.73%	1.78%	0.76%
Old myocardial infarction	4.42%	4.44%	2.29%
Congestive heart failure	9.21%	8.72%	3.50%
Peripheral vascular disease	3.54%	3.43%	1.51%
Cerebrovascular disease	4.78%	4.64%	1.97%
Chronic pulmonary disease	18.84%	19.06%	12.54%
Dementia	1.12%	1.01%	0.31%
Hemiplegia or paraplegia	1.72%	1.90%	0.84%
Diabetes with or without complications	16.87%	16.31%	11.31%
Chronic renal failure	5.74%	5.74%	2.28%
Mild liver disease/Cirrhodities	2.14%	2.03%	1.00%
Moderate to severe liver disease	1.41%	1.53%	0.69%
Peptic Ulcer disease	3.22%	3.03%	1.18%
Rheumatologic disease	1.59%	1.59%	1.03%
AIDS	0.80%	0.70%	0.38%

*extra cases added are those that only had encounters in the 6 months after cancer diagnosis

Supplemental Table 3C. Frequency distribution of comorbid conditions identified by using encounters from the 12 months preceding cancer diagnosis compared to conditions identified from encounters in the 6 months following cancer diagnosis

Comorbidity	Frequency of comorbid conditions identified by encounters in the 12 months preceding cancer diagnosis		Frequency of comorbid conditions identified by encounters in the 6 months following cancer diagnosis	
	N	%	N	%
Acute myocardial infarction	26,964	2.24%	18,953	2.50%
Old myocardial infarction	68,960	5.73%	45,780	6.04%
Congestive heart failure	143,727	11.94%	81,609	10.77%
Peripheral vascular disease	55,204	4.59%	33,428	4.41%
Cerebrovascular disease	74,638	6.20%	45,238	5.97%
Chronic pulmonary disease	294,006	24.43%	198,408	26.18%
Dementia	17,520	1.46%	8,625	1.14%
Hemiplegia or paraplegia	26,909	2.24%	22,187	2.93%
Diabetes with or without complications	263,363	21.88%	158,139	20.86%
Chronic renal failure	89,535	7.44%	58,740	7.75%
Mild liver disease/Cirrhodities	33,364	2.77%	19,056	2.51%
Moderate to severe liver disease	22,056	1.83%	17,565	2.32%
Peptic Ulcer disease	50,223	4.17%	28,191	3.72%
Rheumatologic disease	24,760	2.06%	16,332	2.15%
AIDS	12,430	1.03%	5,675	0.75%
Total conditions identified	1,203,659	100%	757,926	100%

Supplemental Table 3D. Association of comorbidity score with mortality among California cancer patients. Comparison of multivariate* model results.

Characteristic	Value	Comorbidity score based on including only encounters in the 12 months prior to diagnosis			Comorbidity score based on including 12 months prior and 6 months after diagnosis		
			95% Hazard Ratio Confidence Limits			95% Hazard Ratio Confidence Limits	
		Hazard ratio	Lower	Upper	Hazard ratio	Lower	Upper
Charlson Comorbidity Score	0	reference			reference		
	1	1.43	1.42	1.43	1.50	1.49	1.50
	2	1.67	1.66	1.68	1.79	1.78	1.80
	3 or higher	2.09	2.08	2.10	2.33	2.32	2.34

*covariates included age at diagnosis, sex, race/ethnicity, quintile of neighborhood socioeconomic status, and SEER summary stage